TransCode Therapeutics, Inc., (RNAZ): Price and Financial Metrics
RNAZ Price/Volume Stats
| Current price | $0.48 | 52-week high | $19.42 |
| Prev. close | $0.47 | 52-week low | $0.22 |
| Day low | $0.46 | Volume | 188,900 |
| Day high | $0.49 | Avg. volume | 1,290,232 |
| 50-day MA | $0.46 | Dividend yield | N/A |
| 200-day MA | $0.68 | Market Cap | 8.29M |
RNAZ Stock Price Chart Interactive Chart >
TransCode Therapeutics, Inc., (RNAZ) Company Bio
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts.
RNAZ Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...